Spero Therapeutics Company Leadership
| SPRO Stock | USD 1.19 0.01 0.83% |
Spero Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Spero Therapeutics suggests that virtually all insiders are panicking. Spero Therapeutics employs about 46 people. The company is managed by 10 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 4.6 employees per reported executive.
| Timothy Keutzer President Senior Vice President - Development |
Spero Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-08-27 | Timothy Keutzer | Disposed 2213 @ 1.35 | View | ||
| 2024-08-05 | Sath Shukla | Disposed 17641 @ 1.31 | View | ||
| 2024-08-02 | Sath Shukla | Disposed 14800 @ 1.32 | View |
Monitoring Spero Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Spero |
Spero Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of 0.1048 % which means that it generated a profit of $0.1048 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2581 %, meaning that it created $0.2581 on every $100 dollars invested by stockholders. Spero Therapeutics' management efficiency ratios could be used to measure how well Spero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to 0.13. Also, Return On Capital Employed is likely to grow to 0.16. At this time, Spero Therapeutics' Asset Turnover is very stable compared to the past year.As of the 22nd of November 2024, Common Stock Shares Outstanding is likely to grow to about 55.6 M, while Net Loss is likely to drop (43.9 M).
Spero Therapeutics Workforce Comparison
Spero Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 776. Spero Therapeutics holds roughly 46.0 in number of employees claiming about 6% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.15 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (1.87) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.87. Spero Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spero Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spero Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Spero Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spero Therapeutics Notable Stakeholders
A Spero Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Spero Therapeutics often face trade-offs trying to please all of them. Spero Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Spero Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Timothy Keutzer | Senior Vice President - Development | Profile | |
| Esther Rajavelu | CFO Officer | Profile | |
| Satyavrat CFA | CFO Treasurer | Profile | |
| James Brady | Chief Officer | Profile | |
| Ted Jenkins | VP Relations | Profile | |
| Ian Critchley | Head Microbiology | Profile | |
| Susannah Walpole | Head Operations | Profile | |
| Angela MD | VP Devel | Profile | |
| MBA MD | President, CoFounder | Profile | |
| Tamara LLM | Chief Secretary | Profile |
About Spero Therapeutics Management Performance
The success or failure of an entity such as Spero Therapeutics often depends on how effective the management is. Spero Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Spero management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Spero management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.13 | |
| Return On Capital Employed | 0.15 | 0.16 | |
| Return On Assets | 0.13 | 0.13 | |
| Return On Equity | 0.21 | 0.22 |
Spero Therapeutics Workforce Analysis
Traditionally, organizations such as Spero Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Spero Therapeutics within its industry.Spero Therapeutics Manpower Efficiency
Return on Spero Therapeutics Manpower
| Revenue Per Employee | 2.1M | |
| Revenue Per Executive | 9.7M | |
| Net Income Per Employee | 495.8K | |
| Net Income Per Executive | 2.3M | |
| Working Capital Per Employee | 2M | |
| Working Capital Per Executive | 9.4M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.08 | Revenue Per Share 2.223 | Quarterly Revenue Growth 2.754 | Return On Assets 0.1048 |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.